Navigation Links
Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease
Date:8/28/2007

Preliminary Phase II Results Encouraging and Support Phase III Study

DEERFIELD, Ill., Aug. 28 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) and The Alzheimer's Disease Cooperative Study (ADCS) group today announced the decision to pursue a multi-center U.S. Phase III study evaluating the role of Gammagard Liquid [Immune Globulin Intravenous (Human)] (IGIV), an intravenous immunoglobulin preparation, for the treatment of patients with mild to moderate alzheimer's disease. GAMMAGARD Liquid contains a broad spectrum of immunoglobulins (antibodies), and is indicated as an immunoglobulin replacement therapy in patients with primary immunodeficiency.

GAMMAGARD Liquid is processed from large pools of human plasma. IGIV has been used for almost three decades to treat primary immunodeficiency. IGIV is not currently approved for the treatment of Alzheimer's disease, and to date has not been established to be effective in this indication. The rationale for testing IGIV as a possible treatment for Alzheimer's is based on the presence of natural antibodies that are directed against several forms of beta amyloid. Beta amyloid is a protein found in plaques that accumulate in the brains of patients with Alzheimer's disease, and is considered to play a key role in the cognitive decline observed in these patients. Treatment with naturally occurring antibodies against beta amyloid contained in IGIV may result in clearance of beta amyloid from the brain and dissolution of plaques.

The decision to pursue the Phase III study is based on the results of two completed open-label clinical studies, and the preliminary analysis of interim data from a double-blind, placebo-controlled phase II study by Dr. Norman Relkin and his colleagues at Weill Cornell Medical College in New York City. In this study, 24 patients with mild to moderate Alzheimer's disease were randomly assigned to receive GAMMAGARD Liquid, GAMMAGARD S/D or placebo (eight patients were treated with GAMMAGARD Liquid, eight patients were treated with GAMMAGARD S/D and eight patients received placebo) for six months. Cognitive, behavioral and functional measures were collected at baseline, three months and six months of treatment. The primary endpoints of the Phase II trial were cognitive function (as measured by ADAS-Cog score) and global function (as assessed by ADCS-CGIC rating). The pre-specified criterion for going forward with Phase III was a favorable outcome in IGIV-treated patients relative to those given placebo. Final results of the analysis of the Phase II study are expected later this year.

The Phase II study follows Dr. Relkin's earlier Phase I results in eight patients that were reported at the International Conference on Alzheimer's Disease in Madrid in July, 2006. Although these findings are promising, both studies were small and results must therefore be confirmed in a larger, sufficiently powered study.

The study protocol will be submitted to the U.S. Food and Drug Administration for review in the coming months with the intention of initiating patient recruitment early in 2008. The ADCS Phase III trial is sponsored jointly by the National Institutes of Health and Baxter. The trial will include approximately 35 leading academic centers in the U.S. that are members of ADCS.

GAMMAGARD LIQUID

[Immune Globulin Intravenous (Human)] 10%

GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Important Safety Information

GAMMAGARD LIQUID is contraindicated in patients with known anaphylactic or severe hypersensitivity responses to Immune Globulin (Human). Patients with severe selective IgA deficiency (IgA < 0.05 g/L) may develop anti-IgA antibodies that can result in a severe anaphylactic reaction.

Immune Globulin Intravenous (Human) products have been reported to be

associated with renal dysfunction, acute renal failure, osmotic nephrosis,

and death. Patients predisposed to acute renal failure include patients

with any degree of pre-existing renal insufficiency, diabetes mellitus,

age greater than 65, volume depletion, sepsis, paraproteinemia, or

patients receiving known nephrotoxic drugs. Especially in such patients,

IGIV products should be administered at the minimum concentration

available and the minimum rate of infusion practicable. While these

reports of renal dysfunction and acute renal failure have been associated

with the use of many of the licensed IGIV products, those containing

sucrose as a stabilizer accounted for a disproportionate share of the

total number.

Glycine, an amino acid, is used as a stabilizer. GAMMAGARD

LIQUID does not contain sucrose.

GAMMAGARD LIQUID is made from human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Components used in the packaging of this product are latex-free.

Thrombotic events have been reported in association with IGIV. Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization.

IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin reaction and, rarely, hemolysis.

Aseptic meningitis syndrome (AMS) has been reported to occur infrequently in association with IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.

Various mild and moderate reactions, such as headache, fever, fatigue, chills, flushing, dizziness, urticaria, wheezing or chest tightness, nausea, vomiting, rigors, back pain, chest pain, muscle cramps, and changes in blood pressure may occur with infusions of Immune Globulin Intravenous (Human).

GAMMAGARD S/D

[Immune Globulin Intravenous (Human)]

GAMMAGARD S/D is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

GAMMAGARD S/D must not be used in patients with selective IgA deficiency (IgA, 0.05 g/L) where the IgA deficiency is the only abnormality of concern.

Important Safety Information

Patients may experience severe hypersensitivity reactions or anaphylaxis in the setting of detectable IgA levels following infusion of GAMMAGARD S/D.

Immune Globulin Intravenous (Human) products have been reported to be

associated with renal dysfunction, acute renal failure, osmotic nephrosis,

and death. Patients predisposed to acute renal failure include patients

with any degree of pre-existing renal insufficiency, diabetes mellitus,

age greater than 65, volume depletion, sepsis, paraproteinemia, or

patients receiving known nephrotoxic drugs. Especially in such patients,

IGIV products should be administered at the minimum concentration

available and the minimum rate of infusion practicable. While these

reports of renal dysfunction and acute renal failure have been associated

with the use of many of the licensed IGIV products, those containing

sucrose as a stabilizer accounted for a disproportionate share of the

total number.

GAMMAGARD S/D does not contain sucrose.

GAMMAGARD S/D is made from human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Aseptic meningitis syndrome (AMS) has been reported to occur infrequently in association with IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.

Certain components used in the packaging of GAMMAGARD S/D contain natural rubber latex.

IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin reaction and, rarely, hemolysis.

Thrombotic events have been reported in association with IGIV. Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization.

Various minor reactions, such as mild to moderate hypotension, headache, fatigue, chills, backache, leg cramps, lightheadedness, fever, urticaria, flushing, slight elevation of blood pressure, nausea and vomiting, may occasionally occur.

For full prescribing information for GAMMAGARD LIQUID and GAMMAGARD S/D please go to:

http://www.baxter.com/products/biopharmaceuticals/downloads/gammagard_u s_pi.pd

f (To link to this website, please copy and paste URL in Internet browser)

http://www.baxter.com/products/biopharmaceuticals/downloads/gamliquid_P I.pdf

Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

This release includes forward-looking statements concerning IGIV relating to clinical trials and their timing, as well as potential future uses of the product. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: continuing review of preliminary trial data and the limited number of patients studied to date; additional regulatory and other steps required prior to the initiation of the larger study described in the release; and other risks identified in the company's most recent filing on Form 10-Q and other SEC filings, all of which are available on the company's web site. The company does not undertake to update its forward-looking statements.


'/>"/>
SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
2. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
3. Cortex Area Thinner in Youth with Alzheimers-Related Gene
4. Appendicitis: Evolving Tools to Diagnose a Classic Disease
5. Non-Invasive Diagnostic Tests for Celiac Disease
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. ... a management presentation at the Deutsche Bank 41 st ... 2:50 p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas . ... hour after conclusion of the live event and accessible at ...
(Date:4/26/2016)... DUBLIN , April 26, 2016 ... "Financial Assessment and Credit Risk Analysis of the Biological ... This comprehensive report analyzes the financial assessment ... China . The report provides readers ... key topics all market participants should be aware of. ...
(Date:4/26/2016)... April 26, 2016 ... 2016;9(1):16-20 DOI: http://doi.org/10.17925/USOR.2016.09.01.16 ... Published recently in US Ophthalmic Review, ... Davidson discusses how laser cataract surgery ... cataract surgery: the laser fragments the lens ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s work ... A group of researchers and leaders from Sanford Health were selected to participate ... Its Cultural Impact ” and receive the 2016 Pontifical Key Innovation Award at ...
(Date:4/28/2016)... CA (PRWEB) , ... April 28, 2016 , ... La ... currently number one in Central America and is looking to grow their market share ... for such an exceptional brand as La Sirena Foods and indirectly with ...
(Date:4/28/2016)... ... 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, has ... be held at the University of Montana on April 28-May 1. Varize will compete ... , In order to qualify, Varize needed to place top seven all-around in her ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... a new CDISC standard, Clinical Trial Registry (CTR) XML. Clinical trial registries ... will make it possible to build applications that generate submissions for multiple, ...
(Date:4/28/2016)... ... 28, 2016 , ... Cosmetic Town, an online plastic surgery community, announces the ... was recently revamped and upgraded to allow even more interaction between doctors and patients ... , According to the senior editor of Cosmetic Town, “We are excited that our ...
Breaking Medicine News(10 mins):